Novel Bayesian Adaptive Designs and Their Applications in Cancer Clinical Trials (Q5050425): Difference between revisions

From MaRDI portal
Set OpenAlex properties.
ReferenceBot (talk | contribs)
Changed an Item
 
Property / cites work
 
Property / cites work: A Hierarchical Bayesian Design for Phase I Trials of Novel Combinations of Cancer Therapeutic Agents / rank
 
Normal rank
Property / cites work
 
Property / cites work: Sequential Designs for Phase I Clinical Trials with Late‐Onset Toxicities / rank
 
Normal rank
Property / cites work
 
Property / cites work: The Theory of Response‐Adaptive Randomization in Clinical Trials / rank
 
Normal rank
Property / cites work
 
Property / cites work: Bootstrap aggregating continual reassessment method for dose finding in drug-combination trials / rank
 
Normal rank
Property / cites work
 
Property / cites work: Continual Reassessment Method: A Practical Design for Phase 1 Clinical Trials in Cancer / rank
 
Normal rank
Property / cites work
 
Property / cites work: Q4593275 / rank
 
Normal rank
Property / cites work
 
Property / cites work: Designed Extension of Studies Based on Conditional Power / rank
 
Normal rank
Property / cites work
 
Property / cites work: Optimal Adaptive Designs for Binary Response Trials / rank
 
Normal rank
Property / cites work
 
Property / cites work: Dose-Finding Based on Efficacy-Toxicity Trade-Offs / rank
 
Normal rank
Property / cites work
 
Property / cites work: Dose-Finding with Two Agents in Phase I Oncology Trials / rank
 
Normal rank
Property / cites work
 
Property / cites work: Practical Bayesian Guidelines for Phase IIB Clinical Trials / rank
 
Normal rank
Property / cites work
 
Property / cites work: Bayesian Response-Adaptive Designs for Basket Trials / rank
 
Normal rank
Property / cites work
 
Property / cites work: Bayesian Model Averaging Continual Reassessment Method in Phase I Clinical Trials / rank
 
Normal rank

Latest revision as of 19:41, 30 July 2024

scientific article; zbMATH DE number 7616814
Language Label Description Also known as
English
Novel Bayesian Adaptive Designs and Their Applications in Cancer Clinical Trials
scientific article; zbMATH DE number 7616814

    Statements

    Novel Bayesian Adaptive Designs and Their Applications in Cancer Clinical Trials (English)
    0 references
    15 November 2022
    0 references
    adaptive design
    0 references
    adaptive randomization
    0 references
    Bayesian method
    0 references
    Bayesian adaptive design
    0 references
    Bayesian optimal interval
    0 references
    BATTLE trial
    0 references
    basket trial
    0 references
    binary endpoint
    0 references
    biomarker
    0 references
    BOIN design
    0 references
    BOP2 design
    0 references
    cancer trial
    0 references
    calibration
    0 references
    clinical trial
    0 references
    continual reassessment method
    0 references
    dose finding
    0 references
    dose-limiting toxicity
    0 references
    dose escalation
    0 references
    decision making
    0 references
    Dirichlet distribution
    0 references
    early stopping
    0 references
    efficacy
    0 references
    efficiency
    0 references
    futility
    0 references
    frequentist
    0 references
    GBM AGILE trial
    0 references
    I-SPY2 trial
    0 references
    interim analysis
    0 references
    immunotherapy
    0 references
    master protocol
    0 references
    maximum tolerated dose
    0 references
    model-assisted design
    0 references
    molecularly targeted agent
    0 references
    multinomial endpoint
    0 references
    multiple outcomes
    0 references
    optimal design
    0 references
    operating characteristics
    0 references
    phase I clinical trial
    0 references
    phase II clinical trial
    0 references
    platform trial
    0 references
    posterior probability
    0 references
    predictive probability
    0 references
    randomized trial
    0 references
    statistical inference
    0 references
    sequential monitoring
    0 references
    simulations
    0 references
    time-to-event endpoint
    0 references
    toxicity
    0 references
    umbrella trial
    0 references

    Identifiers